A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Syma Iqbal; Heinz Josef Lenz; David R Gandara; Stephen I. Shibata; Susan Groshen; Timothy W. Synold; Edward M. Newman

doi:10.1007/s00280-013-2171-4

A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Syma Iqbal, Heinz Josef Lenz, David R Gandara, Stephen I. Shibata, Susan Groshen, Timothy W. Synold, Edward M. Newman

Hematology and Oncology

Research output: Contribution to journal › Article

3 Scopus citations

Abstract

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m² preceded by escalating doses of docetaxel 60 mg/m² (75, 90, 100 mg/m²) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m² with oxaliplatin 130 mg/m².

Original language	English (US)
Pages (from-to)	85-91
Number of pages	7
Journal	Cancer Chemotherapy and Pharmacology
Volume	72
Issue number	1
DOIs	https://doi.org/10.1007/s00280-013-2171-4
State	Published - Jul 2013

Fingerprint

Keywords

Docetaxel
Oxaliplatin
Oxaliplatin and Docetaxel
Phase I

ASJC Scopus subject areas

Cancer Research
Oncology
Pharmacology
Pharmacology (medical)
Toxicology

Cite this

Iqbal, S., Lenz, H. J., Gandara, D. R., Shibata, S. I., Groshen, S., Synold, T. W., & Newman, E. M. (2013). A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 72(1), 85-91. https://doi.org/10.1007/s00280-013-2171-4

@article{faac6a17d6774830a4aaa7d1c205f858,

title = "A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors",

abstract = "The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.",

keywords = "Docetaxel, Oxaliplatin, Oxaliplatin and Docetaxel, Phase I",

author = "Syma Iqbal and Lenz, {Heinz Josef} and Gandara, {David R} and Shibata, {Stephen I.} and Susan Groshen and Synold, {Timothy W.} and Newman, {Edward M.}",

year = "2013",

month = jul

doi = "10.1007/s00280-013-2171-4",

language = "English (US)",

volume = "72",

pages = "85--91",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - A phase i trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

AU - Iqbal, Syma

AU - Lenz, Heinz Josef

AU - Gandara, David R

AU - Shibata, Stephen I.

AU - Groshen, Susan

AU - Synold, Timothy W.

AU - Newman, Edward M.

PY - 2013/7

Y1 - 2013/7

N2 - The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

AB - The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

KW - Docetaxel

KW - Oxaliplatin

KW - Oxaliplatin and Docetaxel

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=84879795373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879795373&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2171-4

DO - 10.1007/s00280-013-2171-4

M3 - Article

C2 - 23712328

AN - SCOPUS:84879795373

VL - 72

SP - 85

EP - 91

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -

Access to Document

10.1007/s00280-013-2171-4